Treatment of erectile dysfunction in patients with cardiovascular disease: Guide to drug selection

Drugs

Volumn 64, Issue 14, 2004, Pages 1533-1545

  Jackson, Graham ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; ARGININE; CARDIOVASCULAR AGENT; CIMETIDINE; HORMONE; METOCLOPRAMIDE; NICORANDIL; NITRIC ACID DERIVATIVE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PSYCHOTROPIC AGENT; RANITIDINE; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL; YOHIMBINE;

ATHEROSCLEROSIS; BACKACHE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE MARKER; DIZZINESS; DYSPNEA; ENDOCRINE FUNCTION; ENDOTHELIUM LESION; ERECTILE DYSFUNCTION; EXERCISE TEST; FLUSHING; HEADACHE; HUMAN; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PENIS ERECTION; PHYSIOLOGY; PREVALENCE; PSYCHOGENIC IMPOTENCE; QUALITY OF LIFE; REVIEW; RHINITIS; RISK ASSESSMENT; RISK FACTOR; SEXUAL BEHAVIOR; SIDE EFFECT; SOMNOLENCE; SURGICAL INJURY; SYNCOPE; TREATMENT CONTRAINDICATION; VASCULAR DISEASE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; CARDIOVASCULAR DISEASES; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PRACTICE GUIDELINES;

EID: 3242805249     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464140-00003     Document Type: Review

References (40)

1. NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993; 270: 83-90
2. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
3. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU lnt 1999; 84: 50-6
4. Taylor Nelson AGB Healthcare. Impotence Association Survey: 2000 and 2001
5. Marwick C. Survey says patients expect little physician help on sex. JAMA 1999; 281: 2173-4
6. Eardley I. Pathophysiology of erectile dysfunction. Br J Diabetes Vase Dis 2002; 2: 272-6
7. Giuliano F. Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview. Eur Heart J Suppl 2002; 4 Suppl. 8: H7-H12
8. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251-4
9. Jackson G. Erectile dysfunction and hypertension. Int J Clin Pract 2002; 56: 491-2
10. Kaiser DR, Billups K, Mason C, et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004 Jan 21; 43 (2): 179-84
11. Snow KJ. Erectile dysfunction in patients with diabetes mellitus: advances in treatment with phosphodiesterase type 5 inhibitors. Br J Diabetes Vase Dis 2002; 2: 282-7
12. Bortolotti A, Parazzini F, Colli E, et al. The epidemiology of erectile dysfunction and its risk factors. Int J Androl 1997; 20: 323-34
13. Kirby M, Jackson G, Betteridge J, et al. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 2001; 55: 614-8
14. Pritzker M. The penile stress test: a window to the heart of the man [abstract]? Circulation 1999; 100: 3751
15. Soloman H, Man JW, Wierzbicki AS, et al. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 2003; 91: 230-1
16. Greenstein A, Chen J, Miller H, et al. Does severity of ischaemic coronary disease correlate with erectile function? Int J Impot Res 1997; 9: 123-6
17. Soloman H, Man J, Wierzbicki AS, et al. Erectile dysfunction: cardiovascular risk and the role of the cardiologist. Int J Clin Pract 2003; 57: 96-9
18. Drory Y. Sexual activity and cardiovascular risk. Eur Heart J Suppl 2002; 4 Suppl. H: H13-8
19. Jackson G, Betteridge J, Dean J, et al. A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement: update 2002. Int J Clin Pract 2002; 56: 633-71
20. Drory Y, Fisman EZ, Shapira Y, et al. Ventricular arrhythmias during sexual activity in patients with coronary artery disease. Chest 1996; 109: 922-4
21. Drory Y, Shapira I, Fisman EZ, et al. Myocardial ischaemia during sexual activity in patients with coronary artery disease. Am J Cardiol 1995; 75: 835-7
22. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000; 86: 175-81
23. Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30
24. Brock GB, McMahon CG, Chen KK, et al. Efficiency and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analysis. J Urol 2002; 168: 1332-6
25. Porst H, Rosen R, Padma-Nathan H, et al. Efficacy and tolerability of vardenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at home clinical trial. Int J Impot Res 2001; 13: 192-9
26. Gillies HC, Roblin D, Jackson G. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 2002; 86: 131-41
27. Jackson G. PDE 5 Inhibitors: looking beyond ED. Int J Clin Pract 2003; 57: 159-60
28. Padma-Nathan H, editor. Sildenafil citrate (Viagra®) and erectile dysfunction: a comprehensive four year update on efficacy, safety, and management approaches. Urology 2002; 60 (2B): 1-90
29. Fox KM, Thadani U, Ma PTS, et al. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J 2003; 24: 2206-12
30. Herrman HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1662-6
31. Halcox JPJ, Nour KRA, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation and myocardial ischaemia. J Am Coll Cardiol 2002; 40: 1232-40
32. Katz SD. Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. Congest Heart Fail 2003; 9: 9-15
33. Jackson G, Bedding A, Emmick J, et al. Interaction between tadalafil and two alpha blockers, doxazosin and tamsulosin [abstract]. Int J Impot Res 2003; 15 Suppl. 6: 37
34. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 2006-12
35. Porst H. A comparator trial between sildenafil, tadalafil and vardenafil: preliminary results in 150 patients [abstract]. Int J Impot Res 2003; 15 Suppl. 6: Ps-2-8
36. Heaton JPW. Key issues from the clinical trials of apomorphine SL. World J Urol 2001; 19: 25-3
37. Morales A. Yohimbine in erectile dysfunction: the facts. Int J Impot Res 2000; 12 Suppl. 1: 570-4
38. Zorgniotti AW. Experience with buccal phentolamine mesylate for impotence. Int J Impot Res 1994; 6: 37-41
39. Ali W, Besarani D, Kirby R. Modern treatment of erectile dysfunction. Br J Diabetes Vas Dis 2002; 2: 255-61
40. Jackson G, Betteridge J, Dean J, et al. A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement. Int J Clin Pract 1999; 53 (6): 445-51